Morgan Stanley initiated coverage of Shoulder Innovations (SI) with an Overweight rating and $18 price target Shoulder Innovations is capturing share in “one of the fastest growing ortho segments,” namely the shoulder arthroplasty market, with products that offer a better range of motion for patients, lower revisions rates, and greater stability, the analyst tells investors. The firm thinks clear surgeon adoption trends and underlying margin strength “position the company for meaningful upside,” the analyst added.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SI:
- Shoulder Innovations initiated with a Buy at Jefferies
- Shoulder Innovations initiated with an Overweight at Piper Sandler
- Strong Buy Rating for Shoulder Innovations, Inc. Driven by Market Leadership and High Growth Potential
- Buy Rating for Shoulder Innovations, Inc.: Strong Growth Potential in Shoulder Replacement Market
- Shoulder Innovations initiated with a Buy at Goldman Sachs